Prof. MD. Hüseyin Mertsoylu

Education and Training

• 1992–1999 — Hacettepe University Faculty of Medicine (English Program)

• 2000–2005 — Gazi University Faculty of Medicine, Department of Internal Medicine

• 2006–2009 — Başkent University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology

• 2009–2011 — Compulsory Service, Şanlıurfa Training and Research Hospital, Medical Oncology Specialist

• 2011–2023 — Başkent University Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology

• Associate Professorship: 19.10.2016

• Professorship: 03.12.2021

Languages

• English

Memberships

• Turkish Society of Medical Oncology

• European Society of Medical Oncology (ESMO)

Articles Published in International Peer-reviewed Journals

• Sarıca B, Tufan K, Çekinmez M, Şen O, Önal C, Mertsoylu H, Topkan E, Pehlivan B, Erdoğan B, Altınors N. Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors.. J Neurosurg Sci, 2010; :-.
• Dişel U, Beşen A, Karadeniz C, Mertsoylu H, Sezer A, Köse F, Sümbül T, Gürkut Ö, Muallaoğlu S, Abalı H, Özyılkan Ö. Prevalence of thyroid dysfunction in untreated cancer patients: a cross-sectional study.. Medical Oncology, 2012; :-.
• Sarıca F, Çekinmez M, Tufan K, Şen O, Önal H, Mertsoylu H, Topkan E, Pehlivan B, Erdoğan B, Altunors MN. Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma.. Asian Journal of Neurosurgery, 2012; :-.
• Köse F, Oğuzkurt L, Beşen A, Sümbül T, Sezer A, Karadeniz C, Dişel U, Mertsoylu H, Özyılkan Ö. Effectiveness of percutaneous metal stent placement in cholangiocarcinoma patients with midterm follow-up: Single center experience.. Eur J Radiol, 2012; :-.
• Muallaoğlu S, Dişel U, Mertsoylu H, Beşen A, Karadeniz C, Sümbül T, Abalı H, Özyılkan Ö. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.. Journal of Balkan Union of Oncology, 2013; 18:261-267.
• Köçer NE, Köse F, Karaselçuk F, Beşen A, Mertsoylu H, Özyılkan Ö, Tuncer I. Does Fascin Expression in Diffuse Large B-Cell Lymphomas have a Clinical Impact in Patients Treated with Anthracyclin-Based Chemotherapy Plus Rituximab?. uhod, 2013; :-.
• Sümbül AT, Sezer A, Abalı H, Köse F, Gültepe I, Mertsoylu H, Muallaoğlu S, Özyılkan Ö. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. int urol nephrol, 2014; :-.
• Muallaoğlu S, Karadeniz C, Mertsoylu H, Beşen AA, Sezer A, Sedef AM, Köse F, Özyılkan Ö. The clinicopathological and survival differences between never and ever smokers with non-small cell lung cancer. J BUON, 2014; :-.
• Sezer A, Sümbül AT, Abalı H, Mertsoylu H, Özyılkan Ö. Malignant pleural mesothelioma: a single-center experience in Turkey. med sci monit, 2014; :-.
• Muallaoğlu S, Beşen AA, Ata A, Mertsoylu H, Arıcan A, Kayaselçuk F, Özyılkan Ö. Lack of prognostic significance of C- erbB-2 expression in low- and high- grade astrocytomas. Asian Pacific journal of cancer prevention, 2014; :-.
• Mertsoylu H, Muallaoğlu S, Beşen AA, Erdoğdu S, Sezer A, Sedef AM, Köse F, Arıcan A, Özyılkan Ö. Primary extranodal non-Hodgkin's lymphoma: clinicopathological features, survival and treatment outcome in two cancer centers of southern Turkey. Asian Pacific journal of cancer prevention, 2014; :-.
• Sezer A, Sümbül AT, Abalı H, Mertsoylu H, Muallaoğlu S, Köse F, Özyılkan Ö. Gemcitabine + platinum combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment: a single center experience.. Hepatogastroenterology., 2014; :-.
• Sedef AM, Köse F, Sümbül AT, Doğan Ö, Beşen AA, Tatlı AM, Mertsoylu H, Sezer A, Muallaoğlu S, Özyılkan Ö, Abalı H. Patients with distal intestinal gastric cancer have superior outcome with addition of taxanes to combination chemotherapy, while proximal intestinal and diffuse gastric cancers do not: does biology and location predict chemotherapy benefit?. Med Oncol., 2015; :-.
• Mertsoylu H, Köse F, Sümbül AT, Sedef AM, Doğan Ö, Beşen AA, Parlak C, Fındıkçıoğlu A, Muallaoğlu S, Sezer A, Sakallı H, Özyılkan Ö. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.. Med Sci Monit, 2015; :-.
• Sedef AM, Köse F, Sümbül T, Doğan Ö, Kurşun E, Yurdakul Z, Sümbül G, Mertsoylu H, Sezer A, Özyılkan Ö. Prognostic value of procalcitonin in infection-related mortality of cancer patients. J BUON, 2016; :-.
• Parlak C, Mertsoylu H, Güler OC, Önal C, Topkan E. Definitive Chemoradiation Therapy Following Surgical Resection or Radiosurgery Plus Whole-Brain. International Journal of Radiation Oncology*Biology*Physics, 2016; :-.
• Temi Bakkal Y, Mertsoylu H. A study on basic demographic and disease characteristics of cancer-diagnosed Syrian refugees treated in the border city of Turkey, Sanliurfa; a hospital-based retrospective case series study.. J BUON., 2017
• Topkan E, Mertsoylu H. Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.. J Neurooncol., 2018; :-.
• Muallaoğlu S, Karagün Ö, Mertsoylu H, Beşen AA, Sezer A, Özyılkan Ö. Attributes of cancer patients admitted to the emergency department in one year. World J Emerg, 2018; :-.
• Topkan E, Mertsoylu H. Chemoradiotherapy-induced hemoglobin nadir values and survival in patients with stage III non- small cell lung cancer.. Lung Cancer, 2018; :-.
• Önal HC, Mertsoylu H. The Utility of Pretreatment and Posttreatment Lymphopenia in Cervical Squamous Cell Carcinoma Patients Treated With Definitive Chemoradiotherapy. Int J Gynecol Cancer., 2018; :-.
• Topkan E, Mertsoylu H. Risk Factors for Fatal Pulmonary Hemorrhage following Concurrent Chemoradiotherapy in Stage 3B/C Squamous-Cell Lung Carcinoma Patients. Journal of oncology, 2018; :-.
• Topkan E, Mertsoylu H. Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy. Journal of geriatric oncology, 2019; :-.
• Topkan E, Mertsoylu H. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy. Ear, Nose & Throat Journal, 2019; :-.
• Önal HC, Mertsoylu H. The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Future Oncology, 2019; :-.
• Yıldırım B, Mertsoylu H. Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Strahlentherapie und Onkologie, 2019; :-.
• Topkan E, Mertsoylu H. Baseline hemoglobin <11.0 g/dL has stronger prognostic value than anemia status in nasopharynx cancers treated with chemoradiotherapy. The International journal of biological markers, 2019; :-.
• Topkan E, Mertsoylu H. Pretreatment Photopenia on 18 F-fluorodeoxyglucose Positron Emission Tomography-Computed Tomograpy Scans Predicts Poor Prognosis in Nasopharygeal Cancer Patients Undergoing Concurrrent Chemoradiotherapy. Clinical Expiremental Otorhinolarngology, 2019; :-.
• Topkan E, Mertsoyul H. Prognostic Usefulness Of Advanced Lung Cancer Inflammation Index In Locally-Advanced Pancreatic Carcinoma Patients Treated With Radical Chemoradiotherapy. cancer management and research, 2019; :-.
• Topkan E, Mertsoylu H. Significance of overall concurrent chemoradiotherapy duration on survival outcomes of stage IIIB/C non-small-cell lung carcinoma patients: Analysis of 956 patients. PloS one, 2019; :-.
• Topkan E, Mertsoylu H. Baseline Low Prognostic Nutritional Index Predicts Poor Survival in Locally Advanced Nasopharyngeal Carcinomas Treated With Radical Concurrent Chemoradiotherapy. Ear, Nose & Throat Journal, 2019; :-.
• Özdemir Y, Topkan E, Mertsoylu H, Selek U. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients With Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy. Cancer Manag Res, 2020; :-.
• Topkan E, Mertsoylu H. Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy plus Concurrent and Adjuvant Temozolomide. Mediators of Inflammation, 2020; :-.
• Topkan E, Mertsoylu H. Prognostic Value of C-Reactive Protein to Albumin Ratio in Glioblastoma Multiforme Patients Treated with Concurrent Radiotherapy and Temozolomide. International Journal of Inflammation, 2020; :-.
• Köse F, Mertsoylu H. Clinical characteristics of relapsed ovarian cancer patients with striking response to the bevacizumab at first relapse. Eur.?J.?Gynaecol.?Oncol, 2020; :-.
• Topkan E, Mertsoylu H. Systemic Inflammation Response Index Predicts Survival Outcomes in Glioblastoma Multiforme Patients Treated with Standard Stupp Protocol. Journal of Immunology Research, 2020; :-.
• Topkan E, Mertsoylu H. Low Advanced Lung Cancer Inflammation Index Predicts Poor Prognosis in Locally Advanced Nasopharyngeal Carcinoma□ Patients Treated with Definitive Concurrent Chemoradiotherapy. Journal of Oncology, 2020;
• Topkan E, Mertsoylu H. Comparison of Involved Field Radiotherapy versus Elective Nodal Irradiation in Stage IIIB/C Non-Small-Cell Lung Carcinoma Patients Treated with Concurrent Chemoradiotherapy:A Propensity Score Matching Study. Journal of Oncology, 2020; :-.
• Topkan E, Mertsoylu H. Low Systemic Inflammation Response Index Predicts Good PrognosTreated with Concurrent Chemoradiotherapyis in Locally Advanced Pancreatic Carcinoma Patients. Gastroenterology Research and Practice, 2020; :-.
• Köse F, Mertsoylu H. Clinical Charactestics of Relapsed Ovarioan Cancer Patients with Striking Response to the Bevasiumab an First Relapse. European Journal of Gynaecological Oncology, 2020; :-.
• Köse F, Mertsoylu H. Half Dose Bevasizumab Experiience in Relapsed Overian Cancer Patients in Turkey due to Formal Regulation. JBUON, 2020; :-.
• Sezgin Göksü S, Mertsoylu H. Cetuximab?induced rash is associated with overall survival in patients with recurrent/metastatic squamous cell carcinoma of head and neck□. Cancer Chemotherapy and Pharmacology, 2021; :-.
• Abalı H, Mertsoylu H. A Phase II Study of the Combination of OxaliplatinCapecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study). American Journal of Clinical Oncology, 2021;

National Peer-Reviewed Journal Articles

• Çalıkuşu Z, Sakallı H, Yılmaz B, Mertsoylu H, Akçalı Z, Özyılkan Ö. evre ıv küçük hücre dışı akciğer kanserli oldularda prognostik faktörlerin incelenmesi. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, 2011; :-.

• Sakallı H, Taş D, Karaaslan O, Mertsoylu H, Yılmaz B, Canataroğlu A. Evaluation of Doxorubicin Cardiomyopathy by Signal Averaged Electrocardiography. Cukurova Med J, 2013; :-.

• Sarıca F, Aydemir F, Çekinmez M, Kardeş Ö, Tufan K, Topkan E, Mertsoylu H, Önal C, Kayaselçuk F, Alkan Ö, Altınkaya N, Yıldırım B, Altınörs MN. Yeni Tanı Almış Glioblastoma Hastalarında Temozolomid ile Yapılan Konkomitan Terapi ve Nüks Glioblastoma Olgularında Uygulanan Bevacizumab ve İrinotecan Antianjiyojenik Kombinasyon Terapisi Etkinliği: 10 Yıllık Tedavi Sonuçları. Türk Nöroşir Derg, 2015; :-.

• Sarıca FB, Mertsoylu H. Yeni Tanı Almış Glioblastoma Hastalarında Temozolomid ile. 2016; :-.

• Sedef AM, Mertsoylu H. Non-small-cell lung cancer (NSCLC) harboring driver mutation (EGFR mutation or ALK translocations) with clinical characteristics and management in a real-life setting: a retrospective observational multicenter case series study. Ortadoğu Medical Journal / Ortadoğu Tıp Dergisi, 2018; :-.

• Sedef AM, Mertsoylu H. Clinicohistopathological features and treatment outcomes of neuroendocrine tumors: a single center experience. Cukurova Medical Journal, 2018; :-.

• Sedef AM, Mertsoylu H. Treatment outcomes of early stage endometrial cancer patients: single center experience. Cukurova Medical Journal, 2019; :-.

• Mertsoylu H, Özyılkan Ö. Kanser Hastalarında Kemik ve Kas Sağlığı. Türkiye Klinikleri Tıp Dergisi, 2020; :-.

• Köse F, Abalı H, Sezer A, Mertsoylu H, Dişel U, Özyılkan Ö. Little dose, huge toxicity: profound hematological toxicity of intrathecal methotrexate. Leuk Lymphoma, 2009; :-.

• Köse F, Sakallı H, Sezer A, Mertsoylu H, Pourbagher A, Reyhan M, Özyılkan Ö. Colon adenocarcinoma and solitary tibia metastasis: rare entity. J Gastrointest Cancer, 2009; :-.

• Abalı H, Dişel U, Köse F, Sezer A, Mertsoylu H. Immediate or delayed docetaxel: does progression-free survival really reflect two strategies? J Clin Oncol, 2009; :-.

• Dişel U, Gürküt Ö, Abalı H, Kaleağası H, Mertsoylu H, Özyılkan Ö, Saif M. Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol, 2010; :-.

• Çalıkuşu Z, Ulusan Ş, Sakallı H, Yılmaz B, Mertsoylu H, Akçalı Z, Özyılkan Ö. penil metastazı yapan bir mesane karsinomlu oldu. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, 2010; :-.

• Özkan E, Mertsoylu H, Özardalı H. A case of renal synovial sarcoma treated with adjuvant ifosfamide and doxorubicin. Intern Med, 2011; :-.

• Köse F, Koçer E, Sezer A, Mertsoylu H, Beşen A, Özyılkan Ö. non hogdkin lenfoma, hıv enfeksiyonu ve multisentrik kastleman hastalığı: tek hastalık olarak presentasyonu. Ortadoğu Tıp Dergisi, 2012; :-.

• Abalı H, Sezer A, Mertsoylu H, Köse F. kemoterapi klavuzu. (Hüseyin Abalı, editor), 2012.

• Muallaoğlu S, Dişel U, Tekin A, Mertsoylu H, Abalı H, Özyılkan Ö. Prolonged use of bevacizumab may cause extensive coronary artery thrombosis. J BUON, 2014; :-.

• Sedef AM, Köse F, Doğan Ö, Ergün T, Sezer A, Mertsoylu H, Muallaoğlu S, Beşen A, Özyılkan Ö. Targeted treatment with pazopanib in metastatic soft tissue sarcoma: nearly complete response in two cases. Mol Clin Oncol, 2014; :-.

• Sedef AM, Köse F, Mertsoylu H, Özyılkan Ö. Procalcitonin as a biomarker for infection-related mortality in cancer patients. Curr Opin Support Palliat Care, 2015; 9(2):168–173.

• Sedef AM, Köse F, Sümbül T, Sezer A, Beşen A, Mertsoylu H, Özyılkan Ö. Acute fatal interstitial lung disease in two cases under treatment of crizotinib. Clin Case Rep Rev, 2016; :-.

• Beşen AA, Mertsoylu H. ALK POZİTİF KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİ TEDAVİSİNDE YENİ GELİŞMELER. In: Bilimsel Araştırmalar Kitabı Onkoloji, 2018.

• Beşen AA, Mertsoylu H. REKURREN YÜKSEK GRADLİ GLİOMLARIN TEDAVİSİ VE YÖNETİMİ. In: Onkolojide Güncel Tedavi Yaklaşımları, 2018.

• Köse F, Mertsoylu H, Sedef AM. ONKOLOJİDE DESTEK TEDAVİLER. 2018.

• Beşen AA, Mertsoylu H. ONKOLOJİDE GÜNCEL TEDAVİ YAKLAŞIMLARI. 2018.

• Mertsoylu H, Köse F, Sedef AM. ONKOLOJİDE ÖZEL KONULAR. 2018.

• Topkan E, Mertsoylu H. Chemoradiotherapy of locally-advanced anal canal squamous cell carcinoma: a brief review of outcomes of randomized clinical trials. Journal of Medical Science and Clinical Research, 2019; :-.

• Topkan L, Mertsoylu H. Chemoradiotherapy-induced cochlear toxicity. International Journal of Scientific Research and Management, 2019; :-.

• Pehlivan B, Mertsoylu H. Current management of brainstem gliomas. International Journal of Advanced Research, 2019; :-.

• Mertsoylu H, Beşen AA. EVRE II KOLON KANSERİNDE ADJUVAN KEMOTERAPİ. In: Gastrointestinal Sistem Tümörleri-2, 2019.

• Mertsoylu H. İYİ DİFERANSİYE TİROİD KANSERLERİNDE SİSTEMİK TEDAVİ. In: Baş Boyun ve Santral Sinir Sistemi Tümörleri. Ankara: Akademisyen Kitabevi; 2019. p.265-268.

• Mertsoylu H. EVRE 1 VE EVRE 2 HASTALIKTA ADJUVAN SİSTEMİK TEDAVİ. In: Toraks Tümörleri. Ankara: Akademisyen Kitabevi; 2019. p.137-142.

• Özyılkan A, Mertsoylu H. ÖKÜLER MELANOMDA GÜNCEL YAKLAŞIM. In: Sarkoma ve Cilt Tümörleri, 2019.

• Mertsoylu H. Solid Tümörlerde CAR-T Hücreli Tedavilerin Gelişimi. In: Onkolojide İmmünoterapi, 2020.